DSpace Repository

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

Show simple item record

dc.contributor Universitat de Vic. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Kawana-Tachikawa, A.
dc.contributor.author Llibre, Josep M.
dc.contributor.author Bravo, Isabel
dc.contributor.author Escrig, R.
dc.contributor.author Mothe, B.
dc.contributor.author Puig, Jordi
dc.contributor.author Puertas, M.C.
dc.contributor.author Martinez Picado, Francisco Javier
dc.contributor.author Blanco, Julià
dc.contributor.author Manzardo, C.
dc.contributor.author Miró, J.M.
dc.contributor.author Iwamoto, A.
dc.contributor.author Pozniak, A.L.
dc.contributor.author Gatell, J.M.
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Brander, Christian
dc.date.accessioned 2014-02-28T10:49:35Z
dc.date.available 2014-02-28T10:49:35Z
dc.date.created 2014
dc.date.issued 2014
dc.identifier.citation Kawana-Tachikawa, A., Llibre, J. M., Bravo, I., Escrig, R., Mothe, B., Puig, J., . . . MARAVIBOOST Investigators. (2014). Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. Plos One, 9(1), e87334. doi:10.1371/journal.pone.0087334 ca_ES
dc.identifier.issn 1932-6203
dc.identifier.uri http://hdl.handle.net/10854/2737
dc.description.abstract Background The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Methods Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). Results Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8+ T cells were indistinguishable between the two arms and did not change over time between the groups. Conclusions Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies. ca_ES
dc.format application/pdf
dc.format.extent 11 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Public Library of Science ca_ES
dc.rights Aquest document està subjecte a aquesta llicència Creative Commons ca_ES
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ ca_ES
dc.subject.other Sida -- Tractament ca_ES
dc.title Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1371/journal.pone.0087334
dc.relation.publisherversion http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0087334
dc.rights.accessRights info:eu-repo/semantics/openAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS
dc.indexacio Indexat a WOS/JCR ca_ES

Files in this item

Show simple item record

Aquest document està subjecte a aquesta llicència Creative Commons Except where otherwise noted, this item's license is described as Aquest document està subjecte a aquesta llicència Creative Commons

Search RIUVic

Advanced Search